Insights from a Physician-Led Practice

A new University of Pennsylvania study of 111,000 women links GLP-1 medications to roughly 30% lower breast cancer risk. Here’s a physician’s careful read of what the data does — and doesn’t — prove.

A randomized clinical trial found semaglutide slowed the pace of biological aging by about 9% on a validated epigenetic clock. Here’s the careful read of what the study actually shows — and what it doesn’t yet prove.

9 biological reasons weight gain hits harder after 40 — and a physician’s read of the Mayo Clinic observational study on tirzepatide plus menopausal hormone therapy.

The Washington Post calls it “modern medicine’s largest unplanned neuroscience experiment.” But the most rigorous Alzheimer’s trial of a GLP-1 failed. Here’s what’s signal, what’s noise, and the asterisk for compounded GLP-1 patients.

A Cleveland Clinic team is presenting observational data showing 38–50% lower rates of progression to stage 4 cancer in GLP-1 users, plus 33% lower overall mortality. Here’s what it actually means and what it doesn’t.

Several large telehealth platforms publicly pivoted from compounded GLP-1s. A clear guide for patients deciding what to do next — including how 503A patient-specific compounding still works.

Marketing pages say month-to-month. Terms describe a non-refundable three-month upfront charge. Here’s the 7 questions to ask before you sign up.

If you’re researching affordable compounded tirzepatide and you keep landing on $99-a-month subscription pages, this is the math you’re missing — and what to look for instead.

An honest, transparent comparison of what compounded semaglutide and tirzepatide actually cost across major telehealth providers in 2026 — including hidden membership fees, contract terms, and cancellation policies.

The FLOW trial showed semaglutide reduced major kidney events by 24% in patients with type 2 diabetes and chronic kidney disease — leading to FDA approval. Here’s what it means.

The SELECT trial showed semaglutide reduces major cardiovascular events by 20% in adults with obesity and heart disease — leading to FDA approval. Here’s what it means for women over 40.

A 2024 JAMA Psychiatry study found GLP-1 patients had a ~50% lower rate of new alcohol use disorder diagnoses. Here’s what the research shows — and what it doesn’t.

Walmart, Nestle, and Morgan Stanley have all publicly said the same thing: GLP-1 patients spend less on food, snacks, and alcohol. Here’s what that could mean for your monthly budget.

Weight loss was just the beginning. Here’s what the actual FDA trials show about GLP-1s for your heart, kidneys, joints, cravings, and more — in plain English.

The STEP 9 trial found women who lost weight on a GLP-1 experienced meaningful knee pain reduction — and researchers think it’s more than just the weight loss.

What microdosing actually means, why it's catching on with women over 40, and why doing it without a physician is riskier than TikTok makes it look.

Your friends are losing weight on GLP-1s and you’re happy for them — mostly. Here’s why that feeling is completely normal.

The difference between gray-market research peptides and legitimate physician-prescribed compounded GLP-1s.

A physician walks through the 7 hidden fees that catch women off guard — consultation charges, auto-renewals, dose escalation surprises, and more.

A physician explains the 6 most common reasons women plateau on semaglutide or tirzepatide — and the fixes that actually work.

Thousands of patients are blindsided when GLP-1 savings cards expire, get pulled, or change terms.

A physician's analysis of the $1.8 billion AI telehealth company built on deepfaked patients, fabricated doctors, and FDA violations.

Mislabeled vials, teenage users, necrotizing pancreatitis — a physician's harsh take on the social media peptide underground.

A transparent look at which therapies have strong clinical evidence, which show promise, and which are pure hype.

Retatrutide, orforglipron, amycretin — the next wave of weight loss medications is showing remarkable results in trials.

The "research use only" label is a legal loophole, not a quality standard. Here's what you need to know about purity and contamination.

Why the source of your peptides matters as much as the peptide itself.

Cutting through the hype — what 36 studies tell us about BPC-157's potential for healing, recovery, and gut health.

A physician's honest comparison of compounded tirzepatide and the brand-name version.

A week-by-week guide to starting tirzepatide or semaglutide — what's normal, what's not, and when to contact your physician.